Una combinación de artemisinina, N-acetilcisteína, resveratrol y hesperidina mejora el daño hipocampal y las características patológicas en un modelo experimental de la enfermedad de Alzheimer

phosphorylation, and caspase-3 expression, along with improved neuronal preservation in the hippocampus. These findings suggest that the combined administration of artemisinin, N-acetylcysteine, resveratrol, and hesperidin exerts multi-target neuroprotective effects in an experimental AD model, potentially through modulation of oxidative stress, neuroinflammation, and apoptotic pathways. However, further studies are required to evaluate pharmacokinetics, safety, and translational relevance before clinical © 2026. The Author(s), under exclusive licence to Springer Science+Business